Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines

International Journal of Oncology

Volumn 12, Issue 5, 1998, Pages 1195-1198

  Símová, Jana ^a   Bubeník, Jan ^a   Jandlová, Tána ^a   Indrová, Marie ^a  

^a INSTITUTE OF MATHEMATICS   (Czech Republic)

Author keywords

Gene therapy; Interleukin 2; Irradiated vaccines

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; LIVE VACCINE; MONOCLONAL ANTIBODY; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; GENE THERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; IRRADIATION; MALE; MOUSE; MYELOMA CELL; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR REGRESSION; VACCINATION;

EID: 0031966016     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.12.5.1195     Document Type: Article

References (23)

1. Bubeník J, Voitenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubeníková D, Símová J and'Jandlová T: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice. Immunol Lett 19: 279-282, 1988.
2. Bubeník J, Símová J and Jandlová T: Immunotherapy of cancer using local administration of Iymphoid cells transformed by IL-2 cDNA and constitutively producing IL-2. Immunol Lett 23: 287-292, 1989/1990.
3. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R and Gilboa E: Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 172: 1217-1224, 1990.
4. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HJ, Simons JW, Karasuyama H, Vogelstein B and Frost P: Interleukin 2 production by tumour cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397-403, 1990.
5. Gansbacher B, Zier K, Cronin K, Hantzopoulos PA, Bouchard B, Houghton A, Gilboa E and Golde D: Retroviral gene transfer induced constitutive expression of interleukin-2 or interferon-γ in irradiated human melanoma cells. Blood 80: 2817-2825, 1992.
6. Foa R, Guarini A and Gansbacher B: IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 66: 992-998, 1992.
7. Kearney JF, Radbruch A, Liessgang B and Rajewsky K: A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. J Immunol 123: 1548-1550, 1979.
8. Karasuyama H and Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin-2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol 18: 97-104, 1988.
9. Bubeník J, Perlmann P, Indrová M, Símová J, Jandlová T and Neuwirt J: Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL-2)-containing preparations. Cancer Immunol Immunother 14: 205-206, 1983.
10. Dialynas DP, Quan ZS, Wall KA, Pierres A, Quintáns J, Loken MR, Pierres M and Fitch FW: Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK 1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol 131: 2445-2451, 1983.
11. Sarmiento M, Glasebrook AL and Fitch FW: IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement. J Immunol 125: 2665-2672, 1980.
12. Connor J, Bannerji R, Saito S, Heston W, Fair W and Gilboa E: Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 177: 1127-1134, 1993.
13. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E and Feldman M: Anti-metastatic vaccination of tumour bearing mice with IL-2 gene-inserted tumour cells. Int J Cancer 53: 471-477, 1993.
14. Bubeník J, Símová J, Bubeníková D, Zeuthen J, Indrová M: Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. J Cancer Res Clin Oncol 121: 39-43, 1995.
15. Bubeník J: Cytokine gene-modified vaccines for immunotherapy of cancer. Int J Oncol 6: 45-49, 1995.
16. Porgador A, Feldman M and Eisenbach L: Immunotherapy of tumor metastasis via gene therapy. Nat Immun 13: 113-130, 1994.
17. Gastl G, Finstad CL, Guarini A, Bosl G, Gilboa E, Bander NH and Gansbacher B: Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 52: 6229-6236, 1992.
18. Arienti F, Sulé-Suso J, Melani C, Maccalli C, Belli F, Illeni MT, Anichini A, Cascinelli N, Colombo MO and Parmiani G: Interleukin-2 gene transduced human melanoma cells efficiently stimulate MHC-unrestricted autologous lymphocytes. Hum Gene Ther 5: 1139-1150, 1994.
19. Matsubara H, Tagawa M, Gunji Y, Takenaga K, Sugaya M, Urashima T, Koide Y, Suzuki T, Asano T, Ochiai T, Isono K, Kageyama H, Nakamura Y and Sakiyama S: Study of irradiation effects on cytokine secretion from retrovirally-transduced tumor cells: a model for tumor vaccination. Anticancer Res 16: 645-650, 1996.
20. Abdel-Wahab Z, Dar MM, Hester D, Vervaert C, Gangavalli R, Barber J, Darrow TL and Seigler HF: Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells. Cell Immunol 171: 246-254, 1996.
21. Karp SE, Farber A, Salo JC, Hwu P, Jaffe G, Asher AL, Shiloni E, Restifo NP, Mule JJ and Rosenberg SA: Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. J Immunol 150: 896-908, 1993.
22. Zatloukal K, Schneeberger A, Berger M, Schmidt W, Koszik F, Kutil R, Cotten M, Wagner E, Buschle M, Maass G, Payer E, Stingl G and Birnstiel ML: Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine. J Immunol 154: 3406-3419, 1995.
23. Bubenik J, Rössner P, Bubeníková D, Símová J, Indrová M and Sloncová E: Tumour vaccines expressing IL-2, CD80, and IL-2 plus CD80 gene. Int J Oncol 11: 1213-1219, 1997.